TEST - Catálogo BURRF
   

MHC Class I Antigens In Malignant Cells : Immune Escape And Response To Immunotherapy / by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera.

Por: Colaborador(es): Tipo de material: TextoTextoSeries SpringerBriefs in Cancer Research ; 6Editor: New York, NY : Springer New York : Imprint: Springer, 2013Descripción: viii, 51 páginas 17 ilustraciones, 14 ilustraciones en color. recurso en líneaTipo de contenido:
  • texto
Tipo de medio:
  • computadora
Tipo de portador:
  • recurso en línea
ISBN:
  • 9781461465430
Formatos físicos adicionales: Edición impresa:: Sin títuloClasificación LoC:
  • RC261-271
Recursos en línea:
Contenidos:
Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion.
Resumen: Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.  
Valoración
    Valoración media: 0.0 (0 votos)
No hay ítems correspondientes a este registro

Springer eBooks

Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion.

Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.  

Para consulta fuera de la UANL se requiere clave de acceso remoto.

Universidad Autónoma de Nuevo León
Secretaría de Extensión y Cultura - Dirección de Bibliotecas @
Soportado en Koha